Answers are grounded in this paper and cite their sources.
Retrospective review demonstrates single-segment fronto-orbital advancement provides equivalent cranial expansion with less blood loss in metopic synostosis, highlighting a streamlined surgical...
Objective Metopic synostosis (MS) is commonly corrected using multi-segment fronto-orbital advancement (FOA), including the frontal bone and supraorbital bandeau. Although this technique reliably expands the anterior vault, it is associated with contour irregularities and bandeau step-offs. The single-segment FOA, utilizing a unified parietal bone flap, was developed with the goal of restoring a seamless frontal contour. This study compares morphologic outcomes between single-segment and multi-segment FOA in MS. Design A retrospective review of 3-dimensional imaging of patients with MS who underwent single-segment or multi-segment FOA. Setting Tertiary pediatric institution. Patients, Participants Twenty patients with MS were included (10 single-segment, 10 multi-segment). Ten control patients were included at each time point for comparison. Interventions Single-segment or multi-segment FOA Main Outcome Measure(s) Pre- and 2-week, 1-year, and 2-year postoperative imaging were analyzed to assess craniometric variables and intracranial volumes. Craniofacial composites were created. Results Single-segment FOA demonstrated significantly shorter operative time ( P = 0.003) and reduced blood loss ( P = 0.008). Both groups achieved comparable increases in total (13-15%) and anterior cranial volume (23-28%) postoperatively. Craniometric analysis revealed equivalent improvement in orbital morphology. The interfrontal angle normalized to control levels in the single-segment group but remained significantly different in the multi-segment cohort through 2 years. Conclusions Single-segment FOA provides cranial and orbital morphologic correction equivalent to multi-segment FOA while reducing perioperative burden and limiting osteotomies across the frontal contour. This technique offers an efficient and reliable alternative for appropriately selected patients with MS.
No takes yet. Share an insight, caveat, or question.
Harrison et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: